9 reports of this reaction
1.4% of all HYPERICUM PERFORATUM reports
#17 most reported adverse reaction
TACHYCARDIA is the #17 most commonly reported adverse reaction for HYPERICUM PERFORATUM, manufactured by Energique, Inc. There are 9 FDA adverse event reports linking HYPERICUM PERFORATUM to TACHYCARDIA. This represents approximately 1.4% of all 666 adverse event reports for this drug.
Patients taking HYPERICUM PERFORATUM who experience tachycardia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TACHYCARDIA is a less commonly reported adverse event for HYPERICUM PERFORATUM, but still significant enough to appear in the safety profile.
In addition to tachycardia, the following adverse reactions have been reported for HYPERICUM PERFORATUM:
The following drugs have also been linked to tachycardia in FDA adverse event reports:
TACHYCARDIA has been reported as an adverse event in 9 FDA reports for HYPERICUM PERFORATUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
TACHYCARDIA accounts for approximately 1.4% of all adverse event reports for HYPERICUM PERFORATUM, making it a notable side effect.
If you experience tachycardia while taking HYPERICUM PERFORATUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.